Home
Search
Search Results
Previously Searched
3103 results found
Expand All
Apply All
3103 results found

BIO 2018 Makes History in Boston
BIO One-on-One Partnering  •  Press Release  •  June 7, 2018
Boston, MA – (June 7, 2018) – The 2018 BIO International Convention (BIO 2018) today wrapped up four days of programming under the theme of “Make History.” Hosted by the Biotechnology Innovation Organization(BIO), BIO 2018 attracted thousands of U.S. and international attendees, celebrated innovations that have shaped the past 25 years and recognized the companies, patient groups, academic centers and investors that continue to advance novel solutions to the world’s toughest challenges... 
Read More

BIO Sets the GUINNESS WORLD RECORDS™ Title for the Largest Business Partnering Event
Business Development, BIO One-on-One Partnering  •  Press Release  •  June 6, 2018
Washington, DC (June 6, 2018) – This morning at the Biotechnology Innovation Organization’s (BIO) International Convention in Boston, BIO proudly attempted – and set– the GUINNESS WORLD RECORDS title for the Largest Business Partnering Event.
Read More

South Dakota Governor Dennis Daugaard Presented BIO Lifetime Champion Award
Press Release  •  June 6, 2018
Boston, MA (June 6, 2018) –  The Biotechnology Innovation Organization (BIO) presented South Dakota Governor Dennis Daugaard with a Lifetime Champion Award in recognition of his stalwart leadership and commitment to strengthening South Dakota’s growing biotechnology industry. He received the award in conjunction with the 2018 BIO International Convention."Biotechnology innovation is not just good for South Dakota’s economy. It unlocks the door to important medical, food production, animal health and renewable energy advances as well," said Governor Daugaard. "I am proud to say companies across the biotechnology spectrum have taken notice of what we are doing in South Dakota and have decided to put down roots with us. I am honored to receive this acknowledgement on behalf of the State of South Dakota for our support of innovations that help feed, fuel and heal the world.""Thanks to the leadership of Governor Daugaard, South Dakota has steadily grown and diversified its biotechnology industry," said Jim Greenwood, President and CEO of BIO. "Governor Daugaard has demonstrated his unyielding commitment to building a strong bioscience economy in South Dakota. As a champion of innovation, Governor Daugaard recently signed forward-looking legislation that will provide patients more opportunities to address their medical needs, through the substitution of interchangeable biologic medicines. This bill particularly benefits severely ill patients who rely on complex biological treatments, but also ensures better communications between patients, pharmacists and physicians. We thank him for his service!""Governor Daugaard has been an exemplary leader in enhancing South Dakota’s excellence in the field of biotechnology through strong support for policies that benefit a pro-jobs and pro-biotechnology environment. Governor Daugaard has always been a pro-business advocate for initiatives that support the unique needs of our state’s early-stage companies," said…
Read More

BIO Presents the Henri A. Termeer Biotechnology Visionary Award to Gates Foundation’s Dr. Sue Desmond-Hellmann
Press Release  •  June 6, 2018
Washington, D.C. (June 6, 2018) – The Biotechnology Innovation Organization (BIO) is pleased to announce the establishment of the Henri A. Termeer Biotechnology Visionary Award – created in honor of the late Genzyme CEO who was instrumental in transforming Boston into a thriving hub of life science research, development and innovation... 
Read More

Massachusetts Governor Charlie Baker Presented 2018 BIO Governor of the Year Award
Press Release  •  June 5, 2018
Boston, MA (June 5, 2018) –  The Biotechnology Innovation Organization (BIO) today presented Massachusetts Governor Charlie Baker with its 2018 Governor of the Year award in recognition of his leadership and commitment to strengthening the bioscience industry within Massachusetts. Governor Baker received the award in conjunction with the 2018 BIO International Convention.“The Commonwealth’s life sciences sector is successful because of strong partnerships between state and local government, industry partners and Massachusetts’ leading colleges and universities,” said Governor Charlie Baker. “I am honored to receive this acknowledgement of our administration’s commitment to playing a role in further expanding the industry and we look forward to continuing this collaborative work to ensure Massachusetts remains a leader in the life sciences.”“Governor Baker has been an exemplary leader in enhancing Massachusetts’ world class biotech hub through strong support for economic development policies that benefit a pro-jobs and pro-biotechnology environment,” said Jim Greenwood, President and CEO of BIO. “His support of programs such as tax incentives and capital investments benefit early-stage companies and are powerful tools for attracting and supporting industry growth. The Governor’s leadership in this field will continue to benefit Massachusetts, in terms of jobs and innovation, for years to come.” “Governor Baker and his Administration are true partners to the life sciences. Under his leadership, best exemplified by his filing of the five-year, $500 million next-phase of life sciences initiative, our industry continues to grow across the state as one of the biggest economic drivers for the Massachusetts economy,” said Robert K. Coughlin, President & CEO of MassBio. “What’s most impressive is his understanding of all facets of the sector – from R&D to biomanufacturing to digital health – and his knowledge of what the state must do to…
Read More

BIO Elects New Board Directors and Section Governing Board Chairs
Press Release  •  June 5, 2018
Boston, MA (June 5, 2018) – The Biotechnology Innovation Organization (BIO) is pleased to announce the election of 11 new board directors and several new section governing board chairs and vice chairs at the 2018 BIO International Convention.
Read More

National Bioscience Industry Report Shows $2T Economic Impact, Accelerated Venture Capital Investment & Job Growth
Biotechnology Jobs Report, Council for State Biotechnology Associations (CSBA)  •  Press Release  •  June 5, 2018
A study released today at the BIO International Convention shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator.
Read More

New Bioscience Report Shows Record-Breaking Economic Impact, Accelerated Venture Capital Investment & Job Growth
Press Release  •  June 4, 2018
BIO’s latest report shows that the U.S. bioscience industry has reached record setting annual economic impact, venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry is a leading economic driver and job generator across the U.S., with job growth in 41 states.
Read More

Biofuel and Agriculture Groups Petition EPA Re: Lost RFS Volumes from Small Refinery Exemptions
Letters, Testimony & Comments  •  June 4, 2018
RE: Petition for Reconsideration of 40 C.F.R. §80.1405(c), EPA Docket No. EPA–HQ–OAR–2005–0161, promulgated in 75 Fed. Reg. 14,670 (Mar. 26, 2010); Petition for Reconsideration of Periodic Reviews for the Renewable Fuel Standard Program, 82 Fed. Reg. 58,364 (Dec. 12, 2017)
Read More

Benefit-Risk: BIO Comments on Food and Drug Administration Prescription Drug User Fee Act VI Benefit-Risk Implementation Plan
Letters, Testimony & Comments  •  May 31, 2018
May 31, 2018 Re: Docket No. FDA-2018-N-1010: Food and Drug Administration Prescription Drug User Fee Act VI Benefit-Risk Implementation Plan.Dear Sir/Madam:The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments regarding the Prescription Drug User Fee Act VI Benefit-Risk Implementation Plan.BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.General Comments:BIO supports the FDA's continued efforts to evaluate and improve upon the clarity of the complex and critical process of benefit-risk assessment (B/R assessment) throughout the lifecycle of drug evaluation. While BIO commends the FDA for the great progress in implementing the benefit-risk framework (B/R framework), especially as it relates to transparency and communication of benefit-risk assessments (B/R assessment), additional work is needed to continue to advance and improve upon the current FDA B/R framework. In order to continue to advance the science of B/R assessments and the ability of the framework to inform regulatory decision making, BIO believes that there should be increased emphasis and guidance on the utilization of the B/R framework as a decision support tool, implemented earlier in development, rather than just to support communication following a regulatory decision. For example, the FDA has identified additional opportunities to advance their B/R work, through: (1) incorporation of patient experience into drug development, evaluation, and review and (2) exploration of more quantitative approaches to inform B/R assessments in targeted cases, we ask that these efforts be highlighted as…
Read More